By 2030, it is anticipated that the Turkey Oncology Therapeutics Market will reach a value of $2.8 Bn from $1.5 Bn in 2022, growing at a CAGR of 8.9% during 2022-30. The Oncology Therapeutics Market in Turkey is dominated by a few domestic pharmaceutical companies such as Deva Holding, Mustafa Nevzat, and Abdi İbrahim. The Oncology Therapeutics Market in Turkey is segmented into different types of cancer and different therapy types. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Turkey Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.
By 2030, it is anticipated that the Turkey Oncology Therapeutics Market will reach a value of $2.8 Bn from $1.5 Bn in 2022, growing at a CAGR of 8.9% during 2022-30.
Turkey is an upper middle-income, developing transcontinental country located in Southeastern Europe and Southwestern Asia bordering the Black Sea. In Turkey, public hospitals, hospitals linked with medical colleges, and private hospitals provide health care. Acibadem is a well-known name in the Turkish medical industry. According to the most recent WHO data, the number of new cancer cases in Turkey in 2020 was 2,33,834. On behalf of the Ministry of Health, the cancer registry conducts epidemiological studies and develops Turkey's cancer control policies and national programmes.
Turkey has one of the world's most recognised social security systems, with free healthcare and access to a wide range of cutting-edge cancer medicines. Turkey's government spent 4.6% of its GDP on healthcare in 2020.
Market Growth Drivers Analysis
The Ministry of Health has created a National Cancer Control Program with the goal of preventing cancer, detecting it early, providing high-quality treatment, and improving cancer patients' quality of life. The Turkish Ministry of Health is concerned with all of the country's major diseases and health issues, not just cancer. Currently, 14 Turkish cities, comprising 50.2% of the population, have population-based cancer registry facilities. Medicine prices in Turkey are consistently cheaper than those in several African nations. In Turkey, radiation oncology is an essential component of the multidisciplinary therapy approach. By December 2021, there will be 593 active radiation oncologists. Turkey has become a popular medical tourism destination, with an increasing number of patients seeking high-quality, low-cost oncology care. These aspects could boost Turkey's Oncology Therapeutics Market.
Market restraints
In Turkey, the average cost of oncology operations is $65250. The treatment's high prices can have an impact on its affordability and accessibility among patients. Diagnostic and therapeutic facilities are not evenly distributed throughout the country, and it is critical to make contemporary diagnostic and therapeutic facilities more accessible in rural areas. These factors may deter new entrants into the Turkey Oncology Therapeutics Market.
Key Players
The Turkish Medicines and Medical Devices Agency (TITCK) is the regulatory authority in Turkey in charge of authorising and regulating therapeutic medications. The Turkish Government's Social Security Institution (SSI) reimburses 86 % of the population in the Turkish healthcare system. In 2019, private insurance companies supported 2.9% of the “Health Expenditure Budget of Turkey. The MoH is responsible for licensing drugs in Turkey.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
Oncology Therapeutics Segmentation
By Application (Revenue, USD Billion):
By Drugs (Revenue, USD Billion):
By Therapy (Revenue, USD Billion):
By Route of Administration (Revenue, USD Billion):
By Distribution Channel (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
By 2030, it is anticipated that the Turkey Oncology Therapeutics market will reach a value of $2.8 Bn from $1.5 Bn in 2022, growing at a CAGR of 8.9% during 2022-2030.
In Turkey, the regulatory authority responsible for approving and regulating therapeutic drugs is the Turkish Medicines and Medical Devices Agency (TITCK).
The Oncology Therapeutics Market in Turkey is dominated by a few domestic pharmaceutical companies such as Deva Holding, Mustafa Nevzat, and Abdi İbrahim.